Osteosarcoma immunometabolism: emerging mechanisms and clinical implications

Area of Science:

• Oncology
• Immunology
• Metabolic Research

Background:

• Osteosarcoma (OS) is a primary bone cancer common in adolescents and young adults.
• Current treatments yield poor survival rates for metastatic or recurrent OS, necessitating new therapeutic approaches.
• OS often resists immunotherapy due to disrupted immunometabolic crosstalk.

Purpose of the Study:

• To analyze the current understanding of immunometabolism in osteosarcoma.
• To identify metabolic barriers hindering effective immunotherapy in OS.
• To propose a roadmap for developing targeted, biomarker-driven therapies.

Main Methods:

• Systematic review and critical analysis of existing literature on OS immunometabolism.
• Delineation of OS-specific metabolic reprogramming from general concepts.
• Examination of metabolic alterations within the tumor microenvironment (TME).

Main Results:

• OS cells exhibit unique metabolic reprogramming to support rapid growth.
• Metabolic changes in OS create an immunosuppressive TME, impairing immune cell function.
• Dysregulated immunometabolism is a key factor in OS immunotherapy resistance.

Conclusions:

• Targeting immunometabolic pathways in OS presents a viable strategy to enhance immunotherapy efficacy.
• Understanding OS-specific metabolism is crucial for overcoming therapeutic resistance.
• Biomarker-driven approaches are needed for developing more effective OS treatments.